Lior Y - Search Results

1

Alpha-1 Antitrypsin Substitution for Extrapulmonary Conditions in Alpha-1 Antitrypsin Deficient Patients.

Baranovski BM, Schuster R, Nisim O, Brami I, Lior Y, Lewis EC. Baranovski BM, et al. Among authors: lior y. Chronic Obstr Pulm Dis. 2018 Sep 19;5(4):267-276. doi: 10.15326/jcopdf.5.4.2017.0161. Chronic Obstr Pulm Dis. 2018. PMID: 30723784 Free PMC article.

2

Therapeutic compositions and uses of alpha1-antitrypsin: a patent review (2012 - 2015).

Lior Y, Geyra A, Lewis EC. Lior Y, et al. Expert Opin Ther Pat. 2016 May;26(5):581-9. doi: 10.1517/13543776.2016.1165210. Epub 2016 Mar 25. Expert Opin Ther Pat. 2016. PMID: 26966859 Review.

3

Context-Specific and Immune Cell-Dependent Antitumor Activities of α1-Antitrypsin.

Guttman O, Freixo-Lima GS, Kaner Z, Lior Y, Rider P, Lewis EC. Guttman O, et al. Among authors: lior y. Front Immunol. 2016 Dec 7;7:559. doi: 10.3389/fimmu.2016.00559. eCollection 2016. Front Immunol. 2016. PMID: 28003813 Free PMC article.

4

Point Mutation of a Non-Elastase-Binding Site in Human α1-Antitrypsin Alters Its Anti-Inflammatory Properties.

Lior Y, Zaretsky M, Ochayon DE, Lotysh D, Baranovski BM, Schuster R, Guttman O, Aharoni A, Lewis EC. Lior Y, et al. Front Immunol. 2018 May 1;9:759. doi: 10.3389/fimmu.2018.00759. eCollection 2018. Front Immunol. 2018. PMID: 29780379 Free PMC article.

5

Application of directed evolution and back-to-consensus algorithms to human alpha1-antitrypsin leads to diminished anti-protease activity and augmented anti-inflammatory activities.

Lior Y, Jasevitch M, Ochayon DE, Zaretsky M, Lewis EC, Aharoni A. Lior Y, et al. Cell Immunol. 2020 Sep;355:104135. doi: 10.1016/j.cellimm.2020.104135. Epub 2020 May 21. Cell Immunol. 2020. PMID: 32703529

6

Development of anti-inflammatory peptidomimetics based on the structure of human alpha1-antitrypsin.

Lior Y, Shtriker E, Kahremany S, Lewis EC, Gruzman A. Lior Y, et al. Eur J Med Chem. 2022 Jan 15;228:113969. doi: 10.1016/j.ejmech.2021.113969. Epub 2021 Nov 3. Eur J Med Chem. 2022. PMID: 34763945

7

Fractional exhaled Nitric Oxide (FeNO) level as a predictor of COVID-19 disease severity.

Lior Y, Yatzkan N, Brami I, Yogev Y, Riff R, Hekselman I, Fremder M, Freixo-Lima G, Be'er M, Amirav I, Lavie M. Lior Y, et al. Nitric Oxide. 2022 Jul 1;124:68-73. doi: 10.1016/j.niox.2022.05.002. Epub 2022 May 18. Nitric Oxide. 2022. PMID: 35597408 Free PMC article.

8

Accelerated Wound Border Closure Using a Microemulsion Containing Non-Inhibitory Recombinant α1-Antitrypsin.

Gimmon A, Sherker L, Kojukarov L, Zaknoun M, Lior Y, Fadel T, Schuster R, Lewis EC, Silberstein E. Gimmon A, et al. Among authors: lior y. Int J Mol Sci. 2022 Jul 1;23(13):7364. doi: 10.3390/ijms23137364. Int J Mol Sci. 2022. PMID: 35806370 Free PMC article.

9

Altered Serum Alpha1-Antitrypsin Protease Inhibition before and after Clinical Hematopoietic Stem Cell Transplantation: Association with Risk for Non-Relapse Mortality.

Brami I, Zuckerman T, Ram R, Avni B, Peretz G, Ostrovsky D, Lior Y, Faour C, McElvaney O, McElvaney NG, Lewis EC. Brami I, et al. Among authors: lior y. Int J Mol Sci. 2023 Dec 28;25(1):422. doi: 10.3390/ijms25010422. Int J Mol Sci. 2023. PMID: 38203593 Free PMC article.

10

Intraocular lens implantation as an isolated risk factor for secondary glaucoma in pediatric patients.

Yagev R, Khatib N, Barrett C, Lior Y, Lifshitz T, Tsumi E. Yagev R, et al. Among authors: lior y. Can J Ophthalmol. 2019 Oct;54(5):621-625. doi: 10.1016/j.jcjo.2019.01.003. Epub 2019 Feb 16. Can J Ophthalmol. 2019. PMID: 31564355

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters